Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent (COMPARE-II)

• Major adverse coronary events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  composite of cardiac death, non fatal myocardial infarction and target vessel revascularization
  
  

• Major adverse coronary events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  The combined endpoint of cardiac death, non fatal myocardial infarction, ischemic driven target lesion revascularization (TLR) rate at 12 months follow-up.
  
  
• Safety of stenting with drug eluting stents [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  Incidence of Cardiac Death and Post-Procedural (>48h) MI rate at 12 months, 3 and 5 years
  
  
• Target lesion revascularization [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  Target lesion revascularization at 12 months, 3 and 5 years
  
  
• Late major adverse coronary events [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  The combined endpoint of cardiac death, non fatal myocardial infarction, target vessel revascularization (TVR) rate at 3 and 5 years follow-up.
  
  
• Major adverse coronary events in subgroups [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  The combined endpoint of cardiac death, non fatal myocardial infarction and target vessel revascularization at 12 months, 3 and 5 years in STEMI patients, small vessels (< 2.75 mm RVD), long lesions (> 20 mm), female patients, DM patients and octogenarians
  
  
• Procedural performance [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  Procedural performance at the index procedures, measured by the ability to cross the lesions with the designated DES stent.
  
  
• Stent Thrombosis [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

  Incidence of definite and probable stent thrombosis at 12 months, 3 and 5 years time.

  Incidence of definite, probable or possible stent thrombosis at 12 months, 3 and 5 years time

  
  

The main objective of the study is a head to head comparison of the everolimus eluting XIENCE-V ®, XIENCE-Prime® or PROMUS ® stent with the biolimus A9 eluting NOBORI® stent in order to observe whether there is a difference in clinical outcome between both stents in a real world / all-comer situation.

Clinical outcome of both stents will be assessed by the composite end point of: cardiac death, non fatal myocardial infarction and target vessel revascularization.

Endpoints

The primary end point of the study is the composite of safety (cardiac death, non fatal myocardial infarction) and efficacy (target vessel revascularization) at 12 months.

The secondary end points of the study are:

A) The combined endpoint of cardiac death, non fatal myocardial infarction, ischemic driven target lesion revascularization (TLR) rate at 12 months follow-up.

B) Incidence of Cardiac Death and Post-Procedural (>48h) MI rate at 12 months, 3 and 5 years C) Target lesion revascularization at 12 months, 3 and 5 years D) The combined endpoint of cardiac death, non fatal myocardial infarction, target vessel revascularization (TVR) rate at 3 and 5 years follow-up.

E) The combined endpoint of cardiac death, non fatal myocardial infarction and target vessel revascularization at 12 months, 3 and 5 years in STEMI patients, small vessels (< 2.75 mm RVD), long lesions (> 20 mm), female patients, DM patients and octogenarians. F) Procedural performance at the index procedures, measured by the ability to cross the lesions with the designated DES stent.

G) Incidence of definite and probable stent thrombosis at 12 months, 3 and 5 years time.

H) Incidence of definite, probable and possible stent thrombosis at 12 months, 3 and5 years time.

Overview of the study

This is a prospective, randomized, multi center study. Approximately 2700 patients will be entered in the study and will be randomized on a 2:1 basis. Patients who meet the eligibility criteria will be randomized to the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent versus the Biolimus A9 eluting NOBORI® stent. Patients will be followed for 5 years.

The study population will consist of approximately 2700 patients (1 year enrollment of consecutive all-comers referred for percutaneous coronary intervention (PCI) with coronary artery or by-pass grafts lesions). Patients must meet all eligibility criteria for inclusion into the study.

Randomization will be performed by using a closed envelope with code N for the NOBORI stent and code E for the Everolimus eluting stent. Duration of the study The enrollment phase will start January 2009 and will stop December 2010. The followup phase will last till December 2015.